Revefenacin

Revision as of 04:31, 9 October 2020 by UmaMaveli (talk | contribs)
Jump to navigation Jump to search

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Uma Maveli[2]

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

|blackBoxWarningTitle= WARNING: SERIOUS MENINGOCOCCAL INFECTIONS |blackBoxWarningBody= Life-threatening meningococcal infections/sepsis

  • Comply with the most current Advisory Committee on Immunization Practices (ACIP) recommendations for meningococcal vaccination in patients with complement deficiencies
  • Immunize patients with meningococcal vaccines at least 2 weeks prior to administering the first dose of REVEFENACIN, unless the risks of delaying REVEFENACIN therapy outweigh the risks of developing a meningococcal infection
  • Vaccination reduces, but does not eliminate, the risk of meningococcal infection
    • Monitor patients for early signs of meningococcal infections, and evaluate immediately if infection is suspected

REVEFENACIN is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS). Under the ULTOMIRIS REMS, prescribers must enroll in the program Enrollment in the REVEFENACIN REMS program and additional information are available by telephone: 1-888-765-4747 or at www.ultomirisrems.com.

Dosage

  • The agreed dosage is 175 micrograms per day
    • Taken via a standard jet nebulizer (turns liquid medication into mist) connected to an air compressor
    • Makes it easy for patients with pulmonary problems

Contradictions

Hypersensitivity under any ingredient in Revefenacin

Warnings

See Adverse Reactions

Adverse Reactions

Side Effects

  • Headache
  • Cough
  • Problems regarding the upper respiratory system
  • Back Pain

Drug Interactions

  • Revefenacin and active metabolite (when drug is metabolized by the body into a modified form) are not affected severely smoking status

Use in Specific Populations

  • Revefencin is not affected majorly by age, weight, or gender
  • Hepatic impariment has not been studied to see if there are necessary precautions to take
  • Patients with renal impariment
    • Mesure for antimuscarinic adverse events or the inhibitting of acetocholine, a neurotransmitter in the PNS

IV Compatibility

  • Intravenous solution in healthy volunteers
    • Volume of distribution was 218 L
    • Intravenous solution radioactivity:
    • 54% came out as solid waste
    • 27% came out as liquid waste

Pharmacology

See Clinical Studies

Clinical Studies

Trials:

  • Revefenacin proved to have long duration of action and low systemic exposure (doesn't affect the whole body) for patients struggling with Chronic Obstructive Pulmonary Disease or COPD
  • 88 mcg of this drug can result in constructive bronchodilation (to helps patients breathe better)

Pharmacology trials:

  • Evaluted human recombitance mAChRs (muscarinic cholinergic receptor) by testing it on airway tissues from rats, guinea pigs, and humans
    • Revefenacin proved high affinity for the human tissue and competed against those five human recombinant mAChRs
    • This drug attacked "mAChRs mediated contractile responses"
    • This shows that revefenacin produces long-lasting attacking effects on this tissue from rats, guinea pigs, and humans

Conclusion:

  • Revefenacin has the potential to be a daily dose broncholdilator for patients struggling from COPD

How is it supplied

  • Given to patients via jet nebulizer

Patient Counseling Information

  • Currently Running a 52 week phase three trial for patients with severe OCPD

Precautions with Alcohol

There is limited information on Alcohol-Revefencin interactions. Talk to your doctor for further instruction on consuming alcohol with Revefenacin.

Brand Names

  • Yupelri